Exhibit 99.1

VOLCANO REPORTS THIRD QUARTER RESULTS
COMPANY ANNOUNCES STRATEGIC REPRIORITIZATION INITIATIVE
(SAN DIEGO, CA), November 4, 2013-Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the third quarter and first nine months of 2013.
The company also today announced a strategic reprioritization and reallocation of resources within its distribution, research and development and clinical programs to focus on areas of strong projected growth in FFR (Fractional Flow Reserve), peripheral applications, coronary IVUS (Intravascular Imaging) driven by the ADAPT-DES clinical data and Axsun Medical. This has resulted in a corporate restructuring charge that reflects the discontinuation of certain product development programs effective September 30, 2013.
For the quarter ended September 30, 2013, Volcano reported revenues of $95.8 million versus revenues of $93.7 million in the same period a year ago. On a constant currency basis, revenues increased eight percent year-over-year after adjusting for a negative impact of approximately $5.4 million from foreign currency. Medical segment revenues increased approximately three and nine percent on a reported and constant currency basis, respectively.
The company reported a net loss on a GAAP basis of $8.5 million, or $0.15 per share, in the third quarter of 2013, versus net income of $2.0 million, or $0.04 per diluted share, in the same period a year ago. The results for the third quarter of 2013 included non-cash restructuring charges for the impairment of intangible assets of $4.6 million, acquisition-related expenses of $1.3 million and net interest expense of $6.4 million versus $1.6 million a year ago, reflecting the company’s convertible debt offering completed in the fourth quarter of 2012. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP loss of $0.08 per share.
For the first nine months of 2013, Volcano reported revenues of $290.4 million versus $279.4 million a year ago. This represents an increase of four percent on a reported basis versus the same period a year ago and nine percent on a constant currency basis after adjusting for a $15.1 million negative effect from foreign currency. Medical segment revenues increased five and ten percent on a reported and constant currency basis, respectively. The company reported a net loss on a GAAP basis of $14.0 million, or $0.26 per share, for the first nine months of 2013, versus net income on a GAAP basis of $5.5 million, or $0.10 per diluted share, in the same period a year ago. The results for the first nine months of 2013 include net interest expense of $18.9 million versus $4.3 million a year ago. In addition, the company recorded an expense of $3.7 million related to acquisitions and a gain of $4.1 million related to the sale of a strategic investment, as well as the restructuring charge recorded in the third quarter of 2013. The company also recorded an exchange rate loss of $1.0 million in the first nine months of 2013 versus $319,000 in the same period a year ago. Excluding acquisition-related items, amortization of intangibles and non-cash interest expenses on convertible notes, net of tax, the company reported a non-GAAP net loss per share of $0.03.
“Overall, our business experienced solid growth. Growth drivers included a seven percent increase in our U.S. IVUS revenues, due in great part to a roughly 30 percent increase in peripheral revenues versus the third quarter a year ago, as well as a 27 percent increase in combined revenues in Europe,” said Scott Huennekens, president and chief executive officer.
“At the same time, our U.S. coronary IVUS revenues were impacted by the continued decline in PCI volumes, although we are beginning to see some stabilization in activity. Also, despite the growth in our FFR business in Japan, revenues were not to our expectations,” he added.
“We are finishing 2013 with strong momentum in our market expansion and product development programs. In addition to our growth in the peripheral market and revenues from the sale of the PioneerPlus™ Re-Entry catheter that we acquired during the quarter, we have initiated a limited market release for our Crux® inferior vena cava (IVC) filter and the full market release of our Verrata™ everyday pressure wire,” Huennekens noted.
“Volcano also had a very strong showing at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference. Data from our ADAPT DES study demonstrated the use of IVUS in stent patients changed the procedure 74 percent of the time and was associated with reductions in serious patient events, including stent thrombosis and myocardial infarction, as well as target lesion revascularizations-particularly for patients with more complex lesions. Additionally, the full results from our ADVISE II study showed that a hybrid iFR® (Instant Wave-Free Ratio) approach correctly matched an FFR-only approach in



The following information was filed by Volcano Corp (VOLC) on Monday, November 4, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Volcano Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Volcano Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account